Document:

Certain identified
information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive harm
to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [*].

 

FIRST
Amendment

to

Loan
and security agreement

 

This
First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of October 17, 2019, by and between
Silicon Valley Bank (“Bank”) and OncoCyte Corporation, a California corporation (“Borrower”), whose address
is 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501.

 

Recitals

 

A.
Bank and Borrower have entered into that certain Loan and Security Agreement dated as of February 21, 2017 (as the same may
from time to time be amended, modified, supplemented or restated, the “Loan Agreement”).

 

B.
Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.

 

C.
Borrower has requested that Bank amend the Loan Agreement to (i) make available to Borrower an additional growth capital facility
and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein.

 

D.
Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms,
subject to the conditions and in reliance upon the representations and warranties set forth below.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing
recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to
be legally bound, the parties hereto agree as follows:

 

1.
Definitions.
Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

 

2.
Amendments to Loan Agreement.

 

2.1
Section 2.1.1 (Growth Capital Loan). Section 2.1.1(b)(ii) is amended by adding the following sentence to the end of
such Section:

 

Notwithstanding
the foregoing, the Growth Capital Advances shall be repaid in accordance with Section 2.1.2(a)(i) below.

 

    	 	1	 

    	 

    

 

2.2
Section 2.1.2 (Supplemental Growth Capital Loan). A new Section 2.1.2 is added to the Loan Agreement as follows:

 

2.1.2
Supplemental Growth Capital Loan.

 

(a)
Availability. Subject to the terms and conditions of this Agreement, Bank agrees to make advances to Borrower (each a “Supplemental
Growth Capital Advance” and collectively the “Supplemental Growth Capital Advances”), from time to
time, prior to the Supplemental Growth Capital Commitment Termination Date (Second Tranche), in an aggregate amount not to exceed
the Supplemental Growth Capital Loan Commitment. After repayment, Supplemental Growth Capital Advances may not be reborrowed.

 

(i)
Subject to the terms and conditions hereof, Three Million Dollars ($3,000,000) of the Supplemental Growth Capital Loan Commitment
shall be available in one or more advances of not less than One Million Dollars ($1,000,0000) each, with the first such advance
to be made on or about the First Amendment Date, the proceeds of which shall be used first to immediately repay all Obligations
(including, without limitation, the Final Payment) owing with respect to the Growth Capital Advances with any remaining proceeds
of such Supplemental Growth Capital Advance to be used by Borrower for working capital and other general corporate purposes; provided
however, that Borrower shall not be required to pay a prepayment fee in connection with repayment of the Growth Capital Advances.

 

(ii)
The remaining Two Million Dollars ($2,000,000) of the Supplemental Growth Capital Loan Commitment (the “Supplemental
Second Tranche”) shall be available through the Supplemental Growth Capital Commitment Termination Date (Second Tranche),
provided Borrower has achieved either (a) the Supplemental Second Tranche Milestone or (b) the Equity Milestone. Funds will be
available under the Supplemental Second Tranche as soon as Borrower delivers to Bank evidence satisfactory to Bank that Borrower
has achieved either (a) the Supplemental Second Tranche Milestone or (b) the Equity Milestone. Each Supplemental Growth Capital
Advance under the Supplemental Second Tranche must be in an amount of not less than One Million Dollars ($1,000,000).

 

(b)
Repayment of Supplemental Growth Capital Advances.

 

(i)
Interest-Only Payments. For each Supplemental Growth Capital Advance, Borrower shall make monthly payments of interest-only
commencing on the first (1st) Business Day of the first (1st) month following the month in which the Funding
Date occurs with respect to such Supplemental Growth Capital Advance and continuing thereafter during the Supplemental Interest-Only
Period, on the first (1st) Business Day of each successive month.

 

(ii)
Principal and Interest Payments. For each Supplemental Growth Capital Advance outstanding as of the last day of the Supplemental
Interest-Only Period, Borrower shall make (A) (x) if Borrower does not satisfy the Supplemental Second Tranche Milestone, twenty-four
(24), or (y) if Borrower satisfies the Supplemental Second Tranche Milestone, eighteen (18) consecutive equal monthly payments
of principal commencing on the first (1st) Business Day of the first (1st) month after the Supplemental Interest-Only Period (the
“Supplemental Conversion Date”) and continuing on the on the first (1st) Business Day of each month thereafter,
in amounts that would fully amortize the applicable Supplemental Growth Capital Advance, as of the Supplemental Conversion Date,
over the Supplemental Repayment Period plus (B) monthly payments of accrued and unpaid interest. The Supplemental Final Payment
and all unpaid principal and accrued and unpaid interest on each Supplemental Growth Capital Advance are due and payable in full
on the Supplemental Growth Capital Maturity Date.

 

    	 	2	 

    	 

    

 

(c)
Voluntary Prepayment. Borrower shall have the option to prepay all Supplemental Growth Capital Advances in full, provided
Borrower (i) shall provide written notice to Bank of its election to prepay the Supplemental Growth Capital Advances at least
thirty (30) days prior to such prepayment and (ii) pays, on the date of such prepayment, (A) all outstanding principal and accrued
but unpaid interest, plus (B) the Supplemental Prepayment Fee, plus (C) the Supplemental Final Payment, plus (D) all other sums,
including Bank Expenses, if any, that shall have become due and payable.

 

(d)
Mandatory Prepayment Upon an Acceleration. If the Supplemental Growth Capital Advances are accelerated following the occurrence
of an Event of Default, Borrower shall immediately pay to Bank an amount equal to the sum of (i) all outstanding principal and
accrued but unpaid interest, plus (ii) the Supplemental Prepayment Fee, plus (iii) the Supplemental Final Payment, plus (iv) all
other sums, including Bank Expenses, if any, that shall have become due and payable.

 

2.3
Section 2.2 (Payment of Interest on the Credit Extensions). Section 2.2(a) is amended in its entirety and replaced
with the following:

 

(a)
Interest Rates.

 

(i)
Growth Capital Advances. Subject to Section 2.2(b), the principal amount outstanding for each Growth Capital Advance shall
accrue interest at a floating per annum rate equal to the greater of (i) three-quarters of one percent (0.75%) above the Prime
Rate or (ii) four and one-quarter percent (4.25%), which interest shall be payable monthly.

 

(ii)
Supplemental Growth Capital Advances. Subject to Section 2.2(b), the principal amount outstanding for each Supplemental
Growth Capital Advance shall accrue interest at a floating per annum rate equal to the greater of (i) the Prime Rate or (ii) [five
percent (5.00%) OR INDICATIVE RATE AT CLOSING], which interest shall be payable monthly.

 

2.4
Section 2.3 (Fees). Section 2.3(b) is amended in its entirety and replaced with the following:

 

(b)
Final Payments.

 

(i)
Final Payment. The Final Payment, when due hereunder;

 

(ii)
Supplemental Final Payment. The Supplemental Final Payment, when due hereunder;

 

    	 	3	 

    	 

    

 

2.5
Section 6.2 (Financial Statements, Reports, Certificates). Section 6.2 is amended by deleting the “and”
at the end of clause (j), renumbering clause (k) to be clause (l), and inserting a new clause (k) as follows:

 

(k)
Beneficial Ownership. Prompt written notice of any changes to the beneficial ownership information set out in sections
2.d, 2.e, 2.f, and 2.g of the Perfection Certificate (or any equivalent sections of any Perfection Certificate delivered after
the First Amendment Date). Borrower understands and acknowledges that Bank relies on such true, accurate and up-to-date beneficial
ownership information to meet Bank’s regulatory obligations to obtain, verify and record information about the beneficial
owners of its legal entity customers; and

 

2.6
Section 6.10 (Access to Collateral; Books and Records). The last sentence of Section 6.10 is amended in its entirety
and replaced with the following:

 

In
the event Borrower and Bank schedule an audit more than eight (8) days in advance, and Borrower cancels or seeks to reschedule
the audit with less than eight (8) days written notice to Bank, then (without limiting any of Bank’s rights or remedies),
Borrower shall pay Bank a fee of Two Thousand Dollars ($2,000) plus any out-of-pocket expenses incurred by Bank to compensate
Bank for the anticipated costs and expenses of the cancellation or rescheduling.

 

2.7
Section 6.11 (Formation or Acquisition of Subsidiaries). Section 6.11 is amended by inserting the parenthetical “(including,
without limitation, pursuant to a Division)” immediately after the phrase “any direct or indirect Subsidiary after
the Effective Date”.

 

2.8
Section 7.1 (Dispositions). Section 7.1 is amended by inserting the parenthetical “(including, without limitation,
pursuant to a Division)” immediately after the phrase “or otherwise dispose of”.

 

2.9
Section 7.2 (Changes in Business, Management, Control or Business Locations). The second paragraph in Section 7.2 is
amended by adding the following sentence to the end thereof:

 

If
Borrower intends to add any new offices or business locations, including warehouses, containing in excess of Twenty-Five Thousand
Dollars ($25,000) of Borrower’s assets or property, then Borrower will first receive the written consent of Bank, and the
landlord of any such new offices or business locations, including warehouses, shall execute and deliver a landlord consent in
form and substance satisfactory to Bank.

 

2.10
Section 7.3 (Mergers or Acquisitions). Section 7.3 is amended by deleting the parenthetical “(including, without
limitation, by the formation of any Subsidiary)” and substituting in lieu thereof “(including, without limitation,
by the formation of any Subsidiary or pursuant to a Division)”.

 

    	 	4	 

    	 

    

 

2.11
Section 8.1 (Payment Default). Section 8.1(b) is amended by deleting the reference to “Growth Capital Maturity
Date” and substituting in lieu thereof “the Supplemental Growth Capital Maturity Date”.

 

2.12
Section 8.11 (Delisting). Section 8.11 is amended by replacing all references to “NYSE MKT” with “NYSE American”.

 

2.13
Section 12.1 (Termination Prior to Maturity Date; Survival). Section 12.1 is amended by deleting the phrase “prior
to the Growth Capital Maturity Date by Borrower in accordance with Section 2.1.1” and substituting in lieu thereof “prior
to the Supplemental Growth Capital Maturity Date by Borrower in accordance with Section 2.1.2(c)”.

 

2.14
Section 13 (Definitions). The following terms and their respective definitions set forth in Section 13.1 are amended
in their entirety and replaced with the following:

 

“Credit
Extension” is any Growth Capital Advance, Supplemental Growth Capital Advance or any other extension of credit by Bank
for Borrower’s benefit under this Agreement.

 

“Warrant”
is, collectively, (a) that certain Warrant to Purchase Stock dated as of the Effective Date executed by Borrower in favor of Bank,
and (b) that certain Warrant to Purchase Stock dated as of the First Amendment Date executed by Borrower in favor of Bank.

 

2.15
Section 13 (Definitions). The following terms and their respective definitions are added to Section 13.1 in the appropriate
alphabetical order:

 

“Division”
means, in reference to any Person which is an entity, the division of such Person into two (2) or more separate Persons, with
the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as
contemplated under Section 18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware
law, or any analogous action taken pursuant to any other applicable law with respect to any corporation, limited liability company,
partnership or other entity.

 

“Equity
Milestone” is receipt by Borrower of at least Twenty Million Dollars ($20,000,000) of net cash proceeds from the sale
of Borrower’s equity securities on or before March 31, 2020 to investors and on terms acceptable to Bank.

 

“First
Amendment Date” is October 17, 2019.

 

“Supplemental
Conversion Date” is defined in Section 2.1.2(b)(ii).

 

“Supplemental
Final Payment” is a payment (in addition to and not a substitution for the regular monthly payments of principal plus
accrued interest) due in accordance with Section 2.1.2 above, equal to the Supplemental Growth Capital Loan Commitment multiplied
by the Supplemental Final Payment Percentage.

 

    	 	5	 

    	 

    

 

“Supplemental
Final Payment Percentage” is four percent (4.0%).

 

“Supplemental
Growth Capital Advance” is defined in Section 2.1.2(a).

 

“Supplemental
Growth Capital Commitment Termination Date (Second Tranche)” is September 30, 2020.

 

“Supplemental
Growth Capital Loan Commitment” is Five Million Dollars ($5,000,000).

 

“Supplemental
Growth Capital Maturity Date” is March 1, 2022.

 

“Supplemental
Interest-Only Period” means, with respect to each Supplemental Growth Capital Advance, the period commencing on the
First Amendment Date and continuing through (a) if Borrower does not satisfy the Supplemental Second Tranche Milestone, March
31, 2020, or (b) if Borrower satisfies the Supplemental Second Tranche Milestone, September 30, 2020.

 

“Supplemental
Prepayment Fee” shall be, with respect to any prepayment of the Supplemental Growth Capital Advances, an amount equal
to (i) three percent (3.00%) of the outstanding principal balance of all Supplemental Growth Capital Advances if such prepayment
occurs on or prior to the first anniversary of First Amendment Date, (ii) two percent (2.00%) of the outstanding principal balance
of all Supplemental Growth Capital Advances if such prepayment occurs after the first anniversary of the First Amendment Date
but on or prior to the second anniversary of the First Amendment Date, or (iii) one percent (1.00%) of the outstanding principal
balance of all Supplemental Growth Capital Advances if such prepayment occurs after the second anniversary of the First Amendment
Date.

 

“Supplemental
Repayment Period” is the period of time commencing on the Supplemental Conversion Date and continuing through the Supplemental
Growth Capital Maturity Date.

 

“Supplemental
Second Tranche” is defined in Section 2.1.2(a)(ii).

 

“Supplemental
Second Tranche Milestone” means receipt by Borrower of a positive final coverage determination from the Centers for
Medicare and Medicaid Services (CMS) for the “Razor Assay” at a minimum price point of at least [*] per test.

 

3.
Limitation of Amendments.

 

3.1
The amendments set forth in Section 2, above, are effective for the purposes set forth herein and shall be limited precisely
as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition
of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or
in connection with any Loan Document.

 

    	 	6	 

    	 

    

 

3.2
This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed
and shall remain in full force and effect.

 

4.
Representations and Warranties.
To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:

 

4.1
Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred
and is continuing;

 

4.2
Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement,
as amended by this Amendment;

 

4.3
The organizational documents of Borrower most recently delivered to Bank remain true, accurate and complete and have not been
amended, supplemented or restated and are and continue to be in full force and effect;

 

4.4
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, have been duly authorized;

 

4.5
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower,
(b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental
or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

 

4.6
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and

 

4.7
This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’
rights.

 

    	 	7	 

    	 

    

 

5.
Integration.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the
subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

 

6.
Counterparts.
This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute
one and the same instrument.

 

7.
Effectiveness.
This Amendment shall be deemed effective upon (a) the due execution and delivery to Bank of this Amendment by each party hereto,
(b) the due execution and delivery to Bank by Borrower of a Corporate Borrowing Certificate, in form and substance satisfactory
to Bank, (c) the due execution and delivery to Bank by Borrower of a Warrant to Purchase Common Stock, in form and substance satisfactory
to Bank, (d) the due execution and delivery to Bank by Borrower of a Perfection Certificate, in form and substance satisfactory
to Bank, and (e) payment of Bank’s legal fees and expenses in connection with the negotiation and preparation of this Amendment.
Bank acknowledges receipt of a good faith deposit in the amount of Twenty-Five Thousand Dollars ($25,000) which shall be applied
to Bank Expenses on the First Amendment Date.

 

[Signature
page follows.]

 

    	 	8	 

    	 

    

 

In
Witness Whereof, the parties hereto have caused
this Amendment to be duly executed and delivered as of the date first written above.

 

	BANK	 	BORROWER
	 	 	 	 	 
	Silicon
    Valley Bank	 	OncoCyte
    Corporation
	 	 	 	 	 
	By:	/s/
    Peter Sletteland	 	By:	/s/
    Mitchell Levine
	Name: 
    	Peter
    Sletteland	 	Name: 	Mitchell
    Levine
	Title:
    	Vice President	 	Title:	Chief
    Financial Officer

 

[Signature
Page to First Amendment to Loan and Security Agreement]THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED
OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT
TO PURCHASE COMMON STOCK

 

Company:
OncoCyte Corporation

 

	Number
    of Shares of Common Stock:	70,410 (the “Initial Shares”) with respect to the first One Million
Dollars ($1,000,000) of Supplemental Growth Capital Advances as defined in the Loan Agreement (the “Initial Supplemental
Growth Capital Advance”), plus all Additional Shares which Holder is entitled to purchase pursuant to Section 1.7

 

	Warrant
    Price:	A
    price per share equal to the lower of (i) the average closing price of a share of Common Stock reported on the Trading Market
    (as defined below) for the 10 consecutive trading days, or (ii) the closing price of a share of Common Stock reported on the
    Trading Market for the trading day, in either case, ending immediately prior to, (x) with respect to the Initial Shares, the
    Issue Date, or (y) with respect to all Additional Shares, the applicable Funding Date (as defined in the Loan Agreement).

 

Issue
Date: October 17, 2019

 

	Expiration
    Date:	October
    17, 2029 See also Section 5.1(b).

 

	Credit
    Facility:	This
    Warrant to Purchase Common Stock (“Warrant”) is issued in connection with that certain Loan and
    Security Agreement of dated February 21, 2017 between Silicon Valley Bank and the Company (as amended, restated, supplemented
    or otherwise modified from time to time, the “Loan Agreement”).

 

THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any successor or permitted assignee
or transferee of this Warrant, “Holder”) is entitled to purchase the number of fully paid and non-assessable
shares (the “Shares”) of the common stock, no par value (the “Common Stock”)
of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above
and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth
in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant
to its parent company, SVB Financial Group.

 

SECTION 1.
EXERCISE.

 

1.1
Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering
to the Company this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix
1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer
of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate
Warrant Price for the Shares being purchased. In no event shall an original ink-signed paper copy of this Warrant be required
for any exercise of a Holder’s rights hereunder, nor shall this Warrant or any physical copy thereof be required to be physically
surrendered at the time of any exercise hereof.

 

    	 	1	 

    	 

    

 

1.2
Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as
specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to
receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the
Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

 

X
= Y(A-B)/A

 

where:

 

	 	X
    =	the
    number of Shares to be issued to the Holder;
	 	 	 
	 	Y
    =	the
    number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company
    in payment of the aggregate Warrant Price);
	 	 	 
	 	A
    =	the
    Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
	 	 	 
	 	B
    =	the
    Warrant Price.

 

1.3
Fair Market Value. If the Company’s Common Stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value
of a Share shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately
before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s
Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of
a Share in its reasonable good faith judgment.

 

1.4
Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set
forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder
upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing
the Shares not so acquired.

 

1.5
Replacement of Warrant.

 

(a)
Paper Original Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation,
the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor
and amount.

 

    	 	2	 

    	 

    

 

(b)
Electronic Original Warrant. If at any time this Warrant is rejected by any person (including but not limited to, paying
or escrow agents) or any such person fails to comply with the terms of this Warrant based on this Warrant being presented to such
person as an electronic record, a printout thereof, or any signature hereto being in electronic form, the Company, shall, promptly
upon Holder’s request without indemnity, execute and deliver to Holder, in lieu of electronic original versions of this
warrant, a new warrant of like tenor and amount in paper form with original signatures.

 

1.6
Treatment of Warrant Upon Acquisition of Company.

 

(a)
Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of
related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the
assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger
or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which
the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own
less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately
after such merger, consolidation or reorganization; or (iii) any sale or other transfer, by the stockholders of the Company, of
shares representing at least a majority of the Company’s then-total outstanding combined voting power. For the sake of clarity,
under no circumstance shall a transaction or series of related transactions between the Company and one or more consolidated subsidiaries
of the Company (or the Company itself) constitute an “Acquisition,” unless another party has ultimately acquired the
assets or voting power described in clauses (i), (ii) or (iii).

 

(b)
Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public
Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would
be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not
exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be Cashless
Exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation
of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations
and warranties in Section 4 of the Warrant as of the date thereof and the Company shall promptly notify the Holder of the
number of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market
value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately
prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public
Acquisition.

 

(c)
Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor
entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities
and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant
as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time
in accordance with the provisions of this Warrant.

 

    	 	3	 

    	 

    

 

(d)
As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements:
(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required
reports and other information under the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing
thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted
from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition
were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that
any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond
six (6) months from the closing of such Acquisition.

 

1.7
Additional Shares.

 

Upon
the funding of each Supplemental Growth Capital Advance (as such term is defined in the Loan Agreement) after the Initial Supplemental
Growth Capital Advance, the Company shall be deemed to have automatically granted to Holder, in addition to the number of Shares
which this Warrant can otherwise be exercised for by Holder, the right to purchase a number of additional Shares equal to (i)
the amount of such Supplemental Growth Capital Advance, multiplied by (ii) the number of Shares equal to 2 bps of Fully Diluted
Ownership, divided by (iii) One Million Dollars ($1,000,000), subject to adjustment pursuant to Section 2 below. All such additional
shares issuable under this Section 1.7 being called the “Additional Shares”).

 

For
the purpose of this Warrant: (a) “bps” means one basis point and is equal to one hundredth of one percent (i.e., 0.0001);
and (b) “Fully Diluted Ownership” means as of any applicable date the sum of the number of shares of Common Stock
then issued and outstanding, plus (x) the number of shares of Common Stock then reserved or available for sale or grant (directly
or through the exercise or settlement of options, restricted stock units, or other rights) under any stock option, stock purchase,
or similar plan for the benefit of employees and/or directors of the Company (a “Plan”), (y) the number of shares
of Common Stock issuable upon the exercise of all then outstanding options, warrants, and similar stock purchase rights other
than those issued or granted under a Plan, and (z) the number of shares of Common Stock issuable upon the conversion or exchange
of any then outstanding equity or debt securities or other instruments (other than those issued or granted under a Plan) that
are by their terms convertible or exchangeable, directly or indirectly, for shares of Common Stock, including but not limited
to any such convertible or exchangeable securities issuable upon the exercise or conversion of any securities described in clause
(y).

 

SECTION 2.
ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 

2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Common Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired,
Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would
have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides
the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares
purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding
shares of the Common Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the
Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 

    	 	4	 

    	 

    

 

2.2
Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Common
Stock are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different
class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class
and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation
of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.
The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions,
replacements or other similar events.

 

2.3
Intentionally Omitted.

 

2.4
Intentionally Omitted.

 

2.5
No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be
issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant,
the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional
interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the
then-effective Warrant Price.

 

2.6
Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Common Stock and/or number of Shares,
the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments
to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written
request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment
and the Warrant Price, class and number of Shares in effect upon the date of such adjustment.

 

SECTION 3.
REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 

3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

 

(a)
The initial Warrant Price, as calculated pursuant to the formula referenced on the first page of this Warrant, will not be greater
than the lower of (i) the average closing price of a share of Common Stock reported on the Trading Market (as defined below) for
the 10 consecutive trading days, or (ii) the closing price of a share of Common Stock reporting on the Trading Market for the
trading day, in either case, ending immediately prior to the Issue Date.

 

(b)
All Shares which may be issued upon the exercise of this Warrant, shall, upon issuance, be duly authorized, validly issued, fully
paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under
applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available
out of its authorized and unissued capital stock such number of securities as will be sufficient to permit the exercise in full
of this Warrant.

 

3.2
Notice of Certain Events. If the Company proposes at any time to:

 

(a) declare
any dividend or distribution upon the outstanding shares of the Company’s Common Stock, whether in cash, property, stock,
or other securities and whether or not a regular cash dividend;

 

    	 	5	 

    	 

    

 

(b) offer
for subscription or sale pro rata to the holders of the outstanding shares of Common Stock any additional shares of any class
or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 

(c) effect
any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Common Stock; or

 

(d) effect
an Acquisition or to liquidate, dissolve or wind up;

 

then,
in connection with each such event, the Company shall give Holder:

 

(1) in
the case of the matters referred to in (a) and (b) above, at least seven (7) Business Days prior written notice of the earlier
to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled thereto) or for
determining rights to vote, if any;

 

(2) in
the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when
the same will take place (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled
to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such reasonable
information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise
to the notice); and

 

(3)
Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s
accounting or reporting requirements with respect to any transaction referred to (a) through (d).

 

SECTION 4.
REPRESENTATIONS, WARRANTIES OF THE HOLDER.

 

The
Holder represents and warrants to the Company as follows:

 

4.1
Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution
within the meaning of the Securities Act of 1933, as amended (the “Act”). Holder also represents that it has not been
formed for the specific purpose of acquiring this Warrant or the Shares.

 

4.2
Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received
or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and the Shares. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the Company and the terms and conditions of the offering of this Warrant and the Shares and
to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

 

    	 	6	 

    	 

    

 

4.3
Investment Experience. Holder understands that the purchase of this Warrant and the Shares involves substantial risk. Holder
has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic
risk of such Holder’s investment in this Warrant and the Shares and has such knowledge and experience in financial or business
matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and the Shares and/or has
a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons
of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such
persons.

 

4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act.

 

4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of the Holder’s investment intent as expressed herein and the correctness of the representations and warranties of Holder
under this Section 4. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely
unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such
registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

 

4.6
No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights or other rights as a shareholder
until the exercise of this Warrant.

 

SECTION 5.
MISCELLANEOUS.

 

5.1
Term and Automatic Conversion Upon Expiration.

 

(a)
Term. Subject to the provisions of Section 1.6 above, and the representations and warranties of Holder under Section
4 being true and correct on the Expiration Date as if made on that date, this Warrant is exercisable in whole or in part at any
time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter.

 

(b)
Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one
Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater
than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exercise to Holder.

 

    	 	7	 

    	 

    

 

5.2
Legends. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall
be imprinted with a legend in substantially the following form:

 

THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER
TO SILICON VALLEY BANK DATED OCTOBER 17, 2019, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED
UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT
FROM SUCH REGISTRATION.

 

5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole
or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company,
as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer
is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such
transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company
shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under
the Act.

 

5.4
Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all
of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes
to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of
the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon
providing the Company with written notice, SVB Financial Group and any subsequent Holder may transfer all or part of this Warrant
or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the
Shares, if any) to any transferee, provided, however, in connection with any such transfer, SVB Financial Group or any subsequent
Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification
number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder
if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with
the Company to be bound by all of the terms and conditions of this Warrant.

 

5.5
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed
delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by electronic mail and such receipt is confirmed in writing
by the recipient, or (iv) on the first Business Day following delivery to a reliable next Business Day courier service, courier
fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by
the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder
shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

 

SVB
Financial Group

Attn:
Treasury Department

3003
Tasman Drive, HC 215

Santa
Clara, CA 95054

Telephone:
(408) 654-7400

Email
address: derivatives@svb.com

 

    	 	8	 

    	 

    

 

Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:

 

OncoCyte
Corporation

Attn:
Mitchell Levine, Chief Financial Officer

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Email:
mlevine@oncocyte.com

 

5.6
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement
of such change, waiver, discharge or termination is sought.

 

5.7
Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant,
the party prevailing in such dispute shall be entitled to collect from the other party all costs reasonably incurred in such dispute,
including reasonable attorneys’ fees.

 

5.8
Counterparts; Electronic Signatures; Status as Certificated Security. This Warrant may be executed in counterparts, all
of which together shall constitute one and the same agreement. Company, Holder and any other party hereto may execute this Warrant
by electronic means and each party hereto recognizes and accepts the use of electronic signatures and records by any other party
hereto in connection with the execution and storage hereof. To the extent that this Warrant or any agreement subject to the terms
hereof or any amendment hereto is executed, recorded or delivered electronically, it shall be binding to the same extent as though
it had been executed on paper with an original ink signature. The fact that this Warrant is executed, signed, stored or delivered
electronically shall not prevent the transfer by any Holder of this Warrant pursuant to Section 5.4 or the enforcement of the
terms hereof. This Warrant, and any copies hereof, shall NOT be deemed to be a “certificated security” within the
meaning of Section 8102(a)(4) of the California Commercial Code. Physical possession of the original of this Warrant or any paper
copy thereof shall confer no special status to the bearer thereof.

 

5.9
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California,
without giving effect to its principles regarding conflicts of law.

 

5.10
Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning
of any provision of this Warrant.

 

5.11
Business Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon
Valley Bank is closed.

 

[Remainder
of page left blank intentionally]

[Signature
page follows]

 

    	 	9	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.

 

	“COMPANY”

        
	 
	 	 
	ONCOCYTE
    CORPORATION	 
	 	 
	By:	/s/
    Mitchell Levine	 
	 	 	 
	Name:	Mitchell
    Levine	 
	 	 	 
	Title:	Chief
    Financial Officer	 

 

	“HOLDER”

        
	 
	 	 
	SILICON
    VALLEY BANK	 
	 	 
	By:	/s/
    Peter Sletteland	 
	 	 	 
	Name:	Peter Sletteland	 
	 	 	 
	Title:	Vice President	 

 

    	 	10	 

    	 

    

 

APPENDIX 1

 

NOTICE
OF EXERCISE

 

1.
The undersigned Holder hereby exercises its right to purchase ___________ shares of the Common Stock of ONCOCYTE CORPORATION (the
“Company”) in accordance with the attached Warrant To Purchase Common Stock, and tenders payment of
the aggregate Warrant Price for such shares as follows:

 

	 	[  ]	Check in the amount
    of $________ payable to the order of the Company enclosed herewith
	 	 	 
	 	[  ]	Wire transfer of
    immediately available funds to the Company’s account
	 	 	 
	 	[  ]	Cashless Exercise
    pursuant to Section 1.2 of the Warrant
	 	 	 
	 	[  ]	Other [Describe]
    __________________________________________

 

2.
Please issue a certificate or certificates representing the Shares in the name specified below:

 

___________________________________________

Holder’s
Name

 

___________________________________________

 

___________________________________________

(Address)

 

3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
Section 4 of the Warrant to Purchase Common Stock as of the date hereof.

 

	 	HOLDER:
	 	 	 
	 	 
	 	 	 
	 	By:	    
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	(Date):	 

 

Appendix
1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]